Insulet Corp (NAS:PODD)
$ 161.27 +2.99 (+1.89%) Market Cap: 11.17 Bil Enterprise Value: 11.64 Bil PE Ratio: 37.51 PB Ratio: 8.57 GF Score: 81/100

Insulet Corp at JPMorgan Healthcare Conference Transcript

Jan 13, 2026 / 07:15PM GMT
Release Date Price: $278.17 (-0.14%)
Robbie Marcus
JPMorgan Chase & Co - Analyst

Hello, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Very happy to host our next session with Insulet. CEO, Ashley McEvoy, will do a presentation followed by some Q&A.

Ashley Mcevoy
Insulet Corp - President, Chief Executive Officer, Director

Thank you, Robbie. Good morning, everyone. It's a pleasure to be here. I am Ashley McEvoy, President and CEO of Insulet, and really looking forward to sharing our story and why we are so energized about the present and importantly, the future.

Before we begin, please note our Safe Harbor statement available on our website, which includes important information about risks and uncertainties.

So at Insulet, our vision is simple and powerful, and that is to create a world where diabetes demands less every day, everywhere. Our mission is born of empathy, driven by ingenuity, proven by science, and reflects what drives all of us at Insulet, which is really to transform the lives of people with diabetes every day.

Let me take a bit

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot